Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug

Bortezomib-Encapsulated CuS/Carbon Dots Nanocomposites for Enhanced Photothermal Therapy via Stabilization of Polyubiquitinated Substrates in the Proteasomal Degradation Pathway

(2020) Ying Yu et al.   ACS Nano

N-glycosylation and ubiquitinylation of PD-L1 do not restrict interaction with BMS-202: A molecular modeling study

(2020) Christian Bailly et al.   COMPUTATIONAL BIOLOGY AND CHEMISTRY

Cisplatin-loaded polymeric complex micelles with a modulated drug/copolymer ratio for improved in vivo performance

(2019) Qiuyue Chen et al.   Acta Biomaterialia

Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma

(2019) Yalin Wang et al.   Acta Biomaterialia

Cisplatin contributes to programmed death-ligand 1 (PD-L1) expression in bladder cancer through ERK1/2 - AP-1 signaling pathway

(2019) Te-Fu Tsai et al.   BIOSCIENCE REPORTS

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review

(2019) Planes-Laine et al.   Cancers

Combretastatin A4 Nanodrug‐Induced MMP9 Amplification Boosts Tumor‐Selective Release of Doxorubicin Prodrug

(2019) Jian Jiang et al.   ADVANCED MATERIALS

Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer

(2019) Ludovic Fournel et al.   CANCER LETTERS

The side effects of platinum-based chemotherapy drugs: a review for chemists

(2018) Rabbab Oun et al.   DALTON TRANSACTIONS

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy

(2018) Anastasia Constantinidou et al.   PHARMACOLOGY & THERAPEUTICS

A dynamic N6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors

(2018) Fei Yan et al.   CELL RESEARCH

Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles

(2018) Shannon Grabosch et al.   ONCOGENE

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1

(2017) François Bertucci et al.   Current Oncology Reports

Bortezomib Increases the Cancer Therapeutic Efficacy of Poly(amino acid)–Doxorubicin

(2017) Na Shen et al.   ACS Biomaterials-Science & Engineering

Bortezomib Increases the Cancer Therapeutic Efficacy of Poly(amino acid)–Doxorubicin

(2017) Na Shen et al.   ACS Biomaterials Science & Engineering

Platinum-based drugs: past, present and future

(2016) Shahana Dilruba et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)

(2016) Krzysztof M. Zak et al.   Oncotarget

Paeonol and danshensu combination attenuates apoptosis in myocardial infarcted rats by inhibiting oxidative stress: Roles of Nrf2/HO-1 and PI3K/Akt pathway

(2016) Hua Li et al.   Scientific Reports

Pembrolizumab (Keytruda)

(2016) Gerry Kwok et al.   Human Vaccines & Immunotherapeutics

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer

(2016) Adrian G. Sacher et al.   JAMA Oncology

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

(2015) J. Peng et al.   CANCER RESEARCH

Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(l-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy

(2015) Haiyang Yu et al.   JOURNAL OF CONTROLLED RELEASE

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Prognostic and predictive value of PDL1 expression in breast cancer

(2015) Renaud Sabatier et al.   Oncotarget

Cisplatin in cancer therapy: Molecular mechanisms of action

(2014) Shaloam Dasari et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Ki67 in breast cancer: prognostic and predictive potential

(2010) Rinat Yerushalmi et al.   LANCET ONCOLOGY

Mechanisms of Cisplatin Nephrotoxicity

(2010) Ronald P. Miller et al.   Toxins